Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the HorizonOn July 25, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that the European Medicines Agency’s CHMP has given a positive opinion for its TRYNGOLZA.

The drug is recommended as an add-on to diet for adults with genetically confirmed familial chylomicronemia syndrome. The disease causes very high triglyceride levels and increases the risk of severe pancreatitis. Management noted that this positive opinion is a step forward towards European Commission approval, which is expected by the end of 2025.

Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency

A scientist in a laboratory making a breakthrough discovery in biotechnology.

The drug has already been approved in the United States, and the phase 3 Balance study showed that TRYNGOLZA significantly reduced triglyceride levels and acute pancreatitis events.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops RNA-targeted medicines for serious diseases, including neurological, cardiovascular, and rare genetic disorders.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.